a Adana Numune Training and Research Hospital , Eye Department , Adana , Turkey.
b Ersin Arslan State Hospital , Eye Clinic , Gaziantep , Turkey.
Ocul Immunol Inflamm. 2017 Oct;25(5):649-653. doi: 10.3109/09273948.2016.1149593. Epub 2016 Mar 25.
To compare the efficiency and ocular side-effect profile of topical loteprednol applied to one eye and topical dexamethasone applied to the other eye in the early period on the same patient who has subepithelial infiltrates (SEI).
The patients who developed bilateral SEI following epidemic keratoconjunctivitis (EKC) were applied topical loteprednol on one eye (group 2) and topical dexamethasone on the other (group 1).
Decrease in the symptoms was faster in the dexamethasone group, but this difference between the groups was not statistically significant (p = 0.073). Both groups were found to have substantial recurrence. However, the difference between the groups was not statistically significant (p = 0.131).
The study has found that in the treatment of SEI, which developed after EKC, statistically similar results can be obtained with loteprednol, which is known to have fewer adverse effects.
比较同一患者双侧上皮下浸润（SEI）早期应用单眼局部氯替泼诺和双眼局部地塞米松的疗效和眼部副作用。
患流行性角膜结膜炎（EKC）后出现双侧 SEI 的患者，一眼应用局部氯替泼诺（2 组），另一眼应用局部地塞米松（1 组）。
地塞米松组症状消退较快，但两组间差异无统计学意义（p = 0.073）。两组均发现有明显复发，但两组间差异无统计学意义（p = 0.131）。
本研究发现，氯替泼诺治疗 EKC 后发生的 SEI 可获得与已知副作用较少的地塞米松相似的统计学结果。
